Discrimination of patients with type 2 myocardial infarction

European Heart Journal

Volumn 38, Issue 47, 2017, Pages 3514-3520

  Neumann, Johannes Tobias ^a,b   Sörensen, Nils Arne ^a   Rübsamen, Nicole ^a   Ojeda, Francisco ^a   Renné, Thomas ^c,d   Qaderi, Vazhma ^a   Teltrop, Elena ^a   Kramer, Solveig ^a   Quantius, Laura ^a   Zeller, Tanja ^a,b   Karakas, Mahir ^a,b   Blankenberg, Stefan ^a,b   Westermann, Dirk ^a,b  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Coronary artery disease; High sensitivity; Myocardial injury; Outcome; Troponin I; Type 2 myocardial infarction

Indexed keywords

BIOLOGICAL MARKER; TROPONIN I;

AGED; CLINICAL DECISION MAKING; CLINICAL DECISION SUPPORT SYSTEM; CLINICAL TRIAL; FEMALE; HEART INFARCTION; HOSPITAL READMISSION; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA;

AGED; BIOMARKERS; CLINICAL DECISION-MAKING; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT READMISSION; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; TROPONIN I;

EID: 85040076169     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx457     Document Type: Article

References (26)

1. Bhuiya FA, Pitts SR, McCaig LF. Emergency department visits for chest pain and abdominal pain: United States, 1999-2008. NCHS Data Brief 2010;43:1-8.
2. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol C, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.
3. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-2567.
4. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolavicius S, Jolly SS, Widimsky P, Avezum A, Rupprecht HJ, Zhu J, Col J, Natarajan MK, Horsman C, Fox KA, Yusuf S; TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360:2165-2175.
5. Sandoval Y, Smith SW, Thordsen SE, Apple FS. Supply/demand type 2 myocardial infarction: should we be paying more attention? J Am Coll Cardiol 2014;63: 2079-2087.
6. Sandoval Y, Thordsen SE, Smith SW, Schulz KM, Murakami MM, Pearce LA, Apple FS. Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality risk. Eur Heart J Acute Cardiovasc Care 2014;3:317-325.
7. Saaby L, Poulsen TS, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J, Thygesen K, Mickley H. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 2013;126:789-797.
8. Szymanski FM, Karpinski G, Platek AE, Majstrak F, Hrynkiewicz-Szymanska A, Kotkowski M, Puchalski B, Filipiak KJ, Opolski G. Clinical characteristics, aetiology and occurrence of type 2 acute myocardial infarction. Kardiol Pol 2014;72: 339-344.
9. Shah AS, McAllister DA, Mills R, Lee KK, Churchhouse AM, Fleming KM, Layden E, Anand A, Fersia O, Joshi NV, Walker S, Jaffe AS, Fox KA, Newby DE, Mills NL. Sensitive troponin assay and the classification of myocardial infarction. Am J Med 2015;128:493-501e3.
10. Baron T, Hambraeus K, Sundstrom J, Erlinge D, Jernberg T, Lindahl B, Group TA. Impact on long-term mortality of presence of obstructive coronary artery disease and classification of myocardial infarction. Am J Med 2016;129:398-406.
11. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Jangaard N, Hosbond S, Diederichsen AC, Thygesen K, Mickley H. Clinical characteristics and outcomes of patients with myocardial infarction, myocardial injury, and nonelevated troponins. Am J Med 2016;129:446 e5-e21.
12. Gaggin HK, Liu Y, Lyass A, van Kimmenade RR, Motiwala SR, Kelly N, Mallick A, Gandhi PU, Ibrahim NE, Simon M, Bhardwaj A, Belcher A, Harisiades JE, Massaro JM, D'agostino RB Sr, Januzzi JL. Incident type 2 myocardial infarction in a cohort of patients undergoing coronary or peripheral arterial angiography. Circulation 2017;135:116-127.
13. Neumann JT, Sorensen NA, Schwemer T, Ojeda F, Bourry R, Sciacca V, Schaefer S, Waldeyer C, Sinning C, Renne T, Than M, Parsonage W, Wildi K, Makarova N, Schnabel RB, Landmesser U, Mueller C, Cullen L, Greenslade J, Zeller T, Blankenberg S, Karakas M, Westermann D. Diagnosis of myocardial infarction using a high-sensitivity troponin I 1-hour algorithm. JAMA Cardiol 2016;1:397-404.
14. Neumann JT, Sörensen NA, Ojeda F, Schwemer T, Lehmacher J, Gönner S, Jarsetz N, Keller T, Schaefer S, Renné T, Landmesser U, Clemmensen P, Makarova N, Schnabel RB, Zeller T, Karakas M, Pickering JW, Than M, Parsonage W, Greenslade J, Cullen L, Westermann D, Blankenberg S. Immediate rule-out of acute myocardial infarction using electrocardiogram and baseline highsensitivity troponin I. Clin Chem 2017;63:394-402.
15. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevatio. Eur Heart J 2011;32: 2999-3054.
16. Zeller T, Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel RB, Tuovinen T, Woodward M, Struthers A, Hughes M, Kee F, Salomaa V, Kuulasmaa K, Blankenberg S; MORGAM Investigators. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J 2014; 35:271-281.
17. Zeller T, Ojeda F, Brunner FJ, Peitsmeyer P, Munzel T, Binder H, Pfeiffer N, Michal M, Wild PS, Blankenberg S, Lackner KJ. High-sensitivity cardiac troponin I in the general population - defining reference populations for the determination of the 99th percentile in the Gutenberg Health Study. Clin Chem Lab Med 2015; 53:699-706.
18. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci LM, Tubaro M, Collinson P, Venge P, Hasin Y, Galvani M, Koenig W, Hamm C, Alpert JS, Katus H, Jaffe AS; Study Group on Biomarkers in Cardiology of ESCWGoACC. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252-2257.
19. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574-1581.
20. Landes U, Bental T, Orvin K, Vaknin-Assa H, Rechavia E, Iakobishvili Z, Lev E, Assali A, Kornowski R. Type 2 myocardial infarction: a descriptive analysis and comparison with type 1 myocardial infarction. J Cardiol 2016;67:51-56.
21. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Hosbond S, Jangaard N, Diederichsen AC, Thygesen K, Mickley H. Prognostic impact of myocardial injury related to various cardiac and noncardiac conditions. Am J Med 2016;129:506-514 e1.
22. Sörensen NA, Neumann JT, Ojeda F, Schwemer T, Renné T, Schnabel RB, Zeller T, Karakas M, Blankenberg S, Westermann D. Challenging the 99th percentile: a lower troponin cutoff leads to low mortality of chest pain patients. Int J Cardiol 2017;232:289-293.
23. Westermann D, Neumann JT, Sorensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol 2017;14:472-483.
24. Alpert JS, Thygesen KA. The case for a revised definition of myocardial infarction - the ongoing conundrum of type 2 myocardial infarction vs. myocardial injury. JAMA Cardiol 2016;1:249-250.
25. Nagele P. The case for a revised definition of myocardial infarction - resolving the ambiguity of type 2 myocardial infarction. JAMA Cardiol 2016;1:247-248.
26. Sandoval Y, Thygesen K. Myocardial infarction type 2 and myocardial injury. Clin Chem 2017;63:101-107.